Creators of the Revolutionary Xenoscope
Request DemoValue Analysis


Product Overview
Request DemoProduct Advantages

Xenoscope 5mm and 10mm disposable HD Laparoscopes

The Xenocor fog-proof HD laparoscope with integrated light-source is used for minimally-invasive, abdominal and thoracic procedures. These innovations in technology benefit patients, facilities and providers because they reduce a number of bio-hazard risk factors, minimize common visualization challenges and eliminate capital expense and reprocessing costs associated with laparoscopic surgery.


The Xenobox is a compact reusable unit which serves as the power supply for the Xenoscope. It is a robust central video processor and universal adapter that integrates seamlessly into any HD monitor or existing hospital video system.

The Xenobox, the 5mm articulating and 10mm Xenoscopes are patent protected and FDA cleared and the Xenobox and the10mm scope have also been CE Marked.


The Xenobox is a compact reusable unit which serves as the power supply for the Xenoscope. It is a robust central video processor and universal adapter that integrates seamlessly into any HD monitor or existing hospital video system.

The Xenobox, the 5mm articulating and 10mm Xenoscopes are patent protected and FDA cleared and the Xenobox and the10mm scope have also been CE Marked.


Product Advantages

Easy To Use

  • Lightweight
  • Compatible with all HD Monitors, TV’s, Tablets and existing O.R. imaging infustructure
  • No capital expenditure or service contracts
  • No cleaning, inspecting or re-processing
  • Ready for use right off the shelf

Consistent HD Visualization

  • Designed to provide HD 1080P image with Clearview Technology (TM)
  • Integrated light source and digital HD camera utilizing plug and play technology
  • Fog proof
  • Consistent image through electrocautery smoke
  • Manual focus to improve workflow


  • Non-conducting shaft removes the risk of electrosurgical arcing
  • Low temperature Illumination removes risk of scope burns
  • Disposable single use device helps reduce the risk of disease transmission
  • Fog proof for consistent image quality


  • Designed to help reduce the risk of disease transmission
  • Saves time and expense of costly cleaning and sterilization
  • No capital expenditure to evaluate and use

Who We Are

XENOCOR, an emerging company that aims to revolutionize minimally invasive laparoscopic surgery, by bringing Xenoscope™an innovative, single–use, HD imaging multi–purpose scope to market. This product promises to replace high capital cost laparoscopic systems and expand the delivery of high quality, non-invasive surgical care to the hundreds of millions of people world–wide.

Our Leadership

Evan Kelso

CEO Xenocor

John Langell


Lane Brooks

Chief Engineer

Tony Watson

VP – Sales and Marketing

Xenocor Founding Story:

Our Board

Dinesh Patel
Shawn Fojtik
Jim Hogan

Mountain Pacific Venture Fund Invests in Laparoscopic Device Company Xenocor

Xenocor’s single-use laparoscope, Xenoscope, increases access to minimally invasive surgical care.

Xenocor Granted Breakthrough Technology Agreement with Premier Inc.

Xenoscope New Disposable Fog-Free Laparoscopic System Made Available to 4,000 Healthcare Facilities in the USA.

USPTO Issues U.S. Patent to Xenocor

Issuance of U.S. Patent No. 10,702,128 Further Bolsters Xenocor’s Intellectual Patent Portfolio Salt Lake City, UT USA June 23, 2020 -- Xenocor, Inc., a privately held company focused on identifying, developing and commercializing innovative and differentiated endoscopes to address significant unmet needs in making...

FDA Clears New Disposable Articulating 5mm Laparoscope

The FDA cleared the new Xenocor Disposable 5mm Articulating Laparoscope for minimally invasive abdominal and thoracic surgery. The Xenoscope 5mm articulating disposable laparoscope is designed to improve image quality, reduce fog, lower hospital costs, and reduce bio-hazard risk for the patient and staff.

Xenoscope™ Receives CE Mark

Xenocor, Inc., an emerging leader in developing a new, revolutionary medical imaging platform that provides the most cost‐effective high definition laparoscopy solutions, announced today that it has received the CE Mark for the Xenoscope systems. The Xenoscope is the first...

10mm Xenoscope™ Wins FDA Fast Track Clearance

Xenocor, Inc., an emerging leader in developing a new, revolutionary medical imaging platform that provides the most cost‐effective high definition laparoscopy solutions, announced today that its first product, the Xenoscope, was 510(k) cleared by the U.S. FDA for marketing and distribution. The Xenoscope is the...
“The difference in visibility is really remarkable. The Clearview Imaging Technology is really a great step forward.”

“The Xenoscope is so much lighter than the laparoscopes we were using in the past. You really notice a difference in fatigue by the end of the surgery!”

"Between the better visibility, lighter construction and the polymer shaft removing the potential for arc burns, I feel that the risks of many of my procedures has been lowered significantly."

U.S. 1-844-XENOCOR
Customer Relations

630 Komas Dr. Suite 200
Salt Lake City UT 84108

Speak With Us Today!

John Langell, Founder

John Langell, Founder

John Langell, MD, PhD, MPH, MBA, FACS is a Stanford-trained minimally invasive general surgeon. He is the inventor of the concept for a new cost-effective laparoscopic platform which led to the development of the XenoscopeTM. Dr. Langell currently serves as both President and Chairman of the Board of Directors for Xenocor Inc. He is also Vice Dean for Innovation and Executive Director of the Center for Medical Innovation at the University of Utah School of Medicine. His research efforts are focused on the translation and commercialization of medical technologies and digital medical therapeutics. His work has resulted in the development of many innovative new devices and software applications in the fields of laparoscopic surgery and patient care access for advanced and resource-poor regions.
Evan Kelso, CEO Xenocor

Evan Kelso, CEO Xenocor

Evan Kelso brings 20 years of successful experience in clinical sales and marketing to lead the commercialization efforts for the Xenocor product line.

During his tenure in the industry he worked for several major healthcare companies including United States Surgical/Medtronic to garner extensive and broad clinical training in multiple surgical fields. At DePuy Synthes Spine he had advanced training to specialize and deepen his clinical knowledge developing a full understanding of the complexity and working relationships for the technologies and processes in the neurospine market.  His job was to introduce innovative products and solutions into the operating room to advance surgical procedures, optimizing outcomes for patients.

Through working very closely with doctors and hospital administrators, he developed comprehensive insider-knowledge for best practices in hospital management and procurement operations, surgical procedures and OR functioning, business and financial analytics/revenue stream, as well as a keen understanding of the product landscape and competitive arena. These insights, along with key relationships he has nurtured, will be brought to bear, ensuring the success of the Xenocor product line. 

In addition, he is properly trained and clinically proficient to support the specialties of general, trauma, GYN, Bariatrics, laparoscopy, CVT and neurospine surgical processes and procedures. 

Prior to his leadership position at Xenocor, he founded Vortex Medical, a national imaging focused disposition company.

Dinesh Patel, Board Member

Dinesh Patel, Board Member

Dr. Patel PhD is the founder and managing director of Patel Family Investments (2014) and co-
founded vSpring Capital ($400 million under management) in 2000 and has been a founding managing director till October 2014.

Prior to vSpring Capital, Dr. Patel was an active angel investor in over 20 biotech and technology companies. From 1985 – 1999 Dr. Patel served as Co-Founder, Chairman of The Board of Directors and President & CEO of TheraTech, Inc., a biotechnology company which he took public and eventually sold to Watson Pharmaceuticals (now Actavis) for $350 million. From 1999 to 2004 he was the Founder, Chairman, President & CEO of Ashni Naturaceuticals, Inc., a company that specializes in the research, development and marketing of clinically tested and patent-protected naturaceutical products. In 1999, Dr. Patel co-founded and was the Chairman of Salus Therapeutics, Inc., a biotechnology company focused on the research and development of nucleic acid-based therapeutics, including antisense and gene therapy drugs. He currently holds 15 US Patents and Foreign Counterparts.

Dr. Patel also served on the board of Mediconnect Global, a worldwide leader in medical record retrieval, digitization, and one of the largest cloud based health information exchange. In March 2012, Mediconnect was acquired by Verisk Analytics (VRSK) for over $377 million.

Dr. Patel serves on several non-profit boards, and has won numerous awards including; 2013 Willem J Kolff Lifetime Achievement Award, the 2011 Father of the Year, 2010 Utah Youth Village Helping Hand Award, 2006 Utah Technology Council Hall of Fame Inductee, 2006 Ellis Island Medal of Honor, US Small Business Administration’s Business Achiever Award, Scientific and Technology Award (State of Utah), Entrepreneur of the Year Award (Mountain West Venture Group) and Scientific and Technology Development Pioneer of Progress Award to name a few. He is also a charter member of The Indus Entrepreneurs (TiE).

Dr. Patel served as co-chair of Governor Huntsman’s transition and he served as the Chairman of the USTAR Governing Authority board from 2006-2014. He is a member of the Life Sciences and Management Board at the University of Pennsylvania , on the University of Michigan’s President’s Advisory Group and on the University of Utah’s National Advisory Council.

Born and raised in Zambia, Africa, Dr. Patel received his bachelor’s degree in Pharmacy at Gujarat University located in Ahmedabad, Gujarat, India, his master’s degree from the Philadelphia College of Pharmacy and his Ph.D. in Physical Pharmacy from the University of Michigan.

Dr. Patel led the firm’s investments in Altea Therapeutics, American Academy, Athena Feminine Technologies, Axial Biotech, Coherex Medical, Exagen Diagnostics, Mirabilis Medica, Numira Biosciences, Lineagen, NanaMR, Q Therapeutics, Scintila, ZARS Pharma and Salus Therapeutics which was acquired by Genta (NASDAQ: GNTA) for $30 million.

Lane Brooks, Chief Engineer

Lane Brooks, Chief Engineer

Lane Brooks received his B.S., M.Eng., and Ph.D. degrees in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology (MIT). He has worked as the lead engineer in camera and image sensor design in various successful startups for 15+ years. He has over 10 issued patents and over 10 publications in peer-reviewed journals. In 2013, he led the system design for the miniature microscope that was awarded the Innovation of the Year by the TheScientist.com. In 2007 he was awarded the National Defense Science and Engineering Fellowship. In 2002, he led the design for a camera awarded the distinction of World’s Thinnest Camera by Guinness World Records and Best of Show at CES. In 1999 his team won first place in the annual MIT Robot Competition.
Tony Watson, VP - Sales and Marketing

Tony Watson, VP - Sales and Marketing

Tony Watson spent 16 years in marketing and sales for medical device companies including Medtronic/Covidien, fine-tuning his understanding of the complex relationships between providers, facilities and vendors. He has extensive go-to-market experience, most recently having developed and implemented a successful marketing strategy, which introduced a product and created a new market for the start-up TTCMed.

He is now focused on getting the Xenocor product portfolio into the broader market in order to lower costs and simplify procedural flow for hospitals, but ultimately to increase access to high quality laparoscopic care.  Tony received his MBA from Carlson School of management at the University of Minnesota. 

Jim Hogan, Board Member

Jim Hogan, Board Member

Jim Hogan is recently retired from Medtronic, the world’s largest medical technology company, where he was Regional President for international markets, and member of the CEO Executive Committee. Prior to his career with Medtronic, he spent 13 years with Pfizer in Sr. European leadership roles. He also founded three medical device start-ups, Biostent, Argomed and Cortrak, all of which had successful exits to major multinational companies. Jim holds undergraduate and graduate degrees from the University of Minnesota.
Troy D'Ambrosio

Troy D'Ambrosio

Board Member

Troy D’Ambrosio is currently the Executive Director of the Lassonde Entrepreneur Institute at the University of Utah, an Associate Dean of the David Eccles School of Business and holds a presidential chair. The Institute assists student and faculty from idea to launch through programs, competitions and curriculum. The Lassonde Institute is ranked #23 by the Princeton Review.

Troy D’Ambrosio is co-founder, officer and director of multiple start-up companies, which attracted over $500 million in capital; include founding Transworld Telecommunications which was sold to Sprint in 1996, Convergence Communications which was sold to Lockheed Martin in 2005and EPM Mining Ventures listed on the Toronto Venture Exchange. He has served as the VP of Investor Relations and Corporate Communication for American Stores Company, an NYSE listed company, and the Director of Mutual Fund Operations for Wasatch Advisors. He graduated from the University of Utah in 1982 and was named the Ernst & Young Entrepreneur of the Year in 2000, a v100 Technology leader in 2008 and Best in State Educational Administrator in 2009.

Shawn Fojtik, Board Member

Shawn Fojtik, Board Member

Shawn Fojtik has 100+ combined issued and pending patents and is co-founder of Distal Access, Control Medical, CIRCA Scientific, and others with experience at GE, Boston Scientific, and Black & Decker.

His experience includes devices for cardiology, interventional radiology & oncology, electrophysiology, and other procedures.

Distal Access’s team commercialized the SPINR high-performance guidewire controller then sold it to Merit Medical in 2015. Then, Distal developed the Resectr, launched it remove uterine polyps in July 2016, and sold it to Boston Scientific in November 2016.

Control Medical’s award-winning platform is used to remove blood clots during heart attack, peripheral vascular disease, deep vein thrombosis, and stroke.

CIRCA Scientific commercialized a self-expanding rapid-sensing catheter-probe that achieved profitability in under 3 years from financing.

Shawn is an Adjunct Assistant Professor of Surgery at the University of Utah with a BS from the University of Illinois and a MA from Harvard University.